Title

Presentation

Ionis Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.56, expectations were $-0.85.

Operator: Good day, and welcome to Ionis’ First Quarter 2020 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.

D. Walke: Thank you, Sabrina. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website that accompany today’s call. . With me this morning are Brett Monia, Chief Executive Officer; Kyle Jenne, Chief Global Product Strategy Officer; and Beth Hougen, Chief Financial Officer. Holly Kordasiewicz, Chief Development Officer; Eugene Schneider, Chief Clinical Development Officer; and Eric Swayze, Executive Vice President of Research, will also join us for the Q&A portion of the call.

I’d like to draw your attention to Slide 3, which contains our forward-looking language statement. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail. And with that, I’ll turn the call over to Brett.

Brett Monia: Thanks, Wade. Good morning, everyone, and thank you for joining us today. Ionis entered 2026 with significant momentum, which continued to accelerate through the first quarter of this year. Our performance to date highlights our strong execution across the business, which positions us to fuel substantial growth for years to come. We are very pleased with the continued success of Tryngolza. Demand continues to grow, reflecting both a compelling clinical profile and strong launch execution by our team. The launch of Tryngolza is now also underway in Europe through our partner, Sobi, expanding access to this transformational therapy for people with FCS. We also continue to advance our launch of DAWNZERA. We’re very encouraged by the strong early trajectory and the breadth of prescribers across patient segments.

Outside the U.S., DAWNZERA received European approval earlier this year and our partner Otsuka has now initiated launch activities across the region. Together, Tryngolza and DAWNZERA give us a strong foundation of a successful commercial execution as we look ahead to 2 additional independent launches this year with more to come. We are on track for the launch of olozorsen in severe hypertriglyceridemia, which represents our first independent launch in a broad patient population. We are pleased to have received priority review by the FDA with the PDUFA date of June 30, reflecting the significant unmet need in SHTG and the groundbreaking results from our landmark core and CORE 2 studies. In these studies, we demonstrated profound and highly statistically significant reductions in triglycerides and acute pancreatitis events, along with favorable safety and tolerability.

Today, based on HCP demand and payer research, we are increasing our annual peak sales estimate for olezarsen from greater than $2 billion to now greater than $3 billion, positioning olezarsen to become Ionis’ first wholly owned multibillion-dollar medicine as the new standard of care for treating patients with severe hypertriglyceridemia. Zilganersen for Alexander’s disease is our second planned independent launch this year and the first from our industry-leading neurology pipeline. Zilganersen is the first and only medicine to demonstrate clinically meaningful and disease-modifying benefit in Alexander’s disease, a devastating and orphan fatal leukodystrophy with no approved treatments today. We submitted our NDA in January. And based on the results of our pivotal study, the FDA accepted our NDA with priority review and a PDUFA date of September 22.

Overall, we are on track to have 3 independent medicines for 4 indications on the market in 2026. Tryngolza for FCS and SHTG, DAWNZERA for HAE and Zilganersen for Alexander disease. This marks a major step in Ionis’ Evolution is a fully integrated commercial biotech company. Complementing our wholly owned portfolio is our partner pipeline, a rich pipeline that continues to advance toward multiple value-driving events this year. Bepirovirsen our potential first-in-class medicine for chronic hepatitis B is on track to launch in the U.S. and Japan this year by our partner, GSK. And just this week, the per version was granted Breakthrough Therapy designation and and accepted for priority review by FDA with a PDUFA date of October 26. Next month at EASL, GSK will present the unprecedented results of the Phase III program in which bepirovirsen achieved statistically significant and clinically meaningful functional cure rates in patients with chronic hepatitis B.

We also remain on track for data from 2 major cardiovascular outcome trials from our partner pipeline this year. The pelacarsen Lp(a) HORIZON trial in patients with elevated Lp(a) and cardiovascular disease and the eplontersen cardio transform trial in transthyretin-mediated cardiomyopathy. Including these programs, along with pepireversen, we expect 5 partner-led launches by the end of next year, creating a diversified stream of royalties and milestones for Ionis with multibillion dollar potential well into the next decade. In addition to our commercial and pipeline achievements, we also delivered strong financial results in the first quarter. As a result of this strong Q1 performance and outlook for the balance of the year, today, we are announcing a significant improvement to our financial guidance, which Beth will cover in details in a few moments.

Ionis has achieved a great deal of late. Our pipeline and our launches are delivering tremendous value, and we continue to strengthen our financial position. But even more importantly, we are well positioned and committed to build on the success to drive far greater value for patients and our shareholders. And with that, I’ll turn the call over to Kyle.

Kyle Jenne: Thank you, Brett. As we enter 2026, Ionis is capitalizing on the exceptional launch momentum we generated in 2025 to drive even greater impact. We are set up for continued success with our independent launches. Tryngolza, demand is accelerating. DAWNZERA early launch metrics are tracking extremely well. And enthusiasm continues to build for our upcoming olezarsen launch in SHTG and zilganersen launch in Alexander’s disease. Bingo continues to build on the strong performance from last year. Q1 was our strongest quarter in terms of demand with patient starts increasing significantly versus prior quarters and patients on treatment are doing extremely well. . Our patient finding initiatives continue to identify appropriate FCS patients, and we are successfully converting prescriptions to patients on treatment.

We are seeing ongoing expansion in both breadth and depth of prescribing with more clinicians initiating Tryngolza and existing prescribers writing additional scripts. Prescribers span a broad mix of specialties, including cardiology, endocrinology and lipidology, which is exactly the prescriber base we want as we prepare for the broader SHTG population. Physicians remain highly satisfied with Tryngolza’s overall profile. Efficacy, safety, tolerability and the patient experience, and that is translating into an accelerating rate for new patient starts. Additionally, we are highly encouraged by the updated ACC and AHA clinical practice guidelines, which singles out olezarsen as the recommended treatment to lower triglycerides and reduce pancreatitis risk in patients with FCS.

Outside the U.S., our partner, Sobi, is now in the early stages of launching Tryngolza for FCS in Europe. This is expanding access for FCS patients and will bring in additional revenue over time. Following the groundbreaking CORE and CORE 2 data and SHTG, we conducted extensive market research with high-volume lipid specialists, cardiologists and endocrinologists. That work consistently showed a clear understanding that preventing pancreatitis is the key treatment goal in SHTG and that current options fall short. Strong recognition of all olezarsen’s differentiated clinical profile, especially the acute pancreatitis data and the very low number needed to treat. And HCPs have stated a high intent to prescribe across a range of patient types with initial use expected for individuals with triglyceride levels above 880 milligrams per deciliter, or above 500 milligrams per deciliter, with a history of acute pancreatitis or other high-risk comorbidities, including progressive cardiovascular disease and type 2 diabetes.

In line with our commitment to patient access and to a successful transition into the broader SHTG market, we recently announced an important pricing decision for Tryngolza. Effective April 1, we set the new annual wholesale acquisition cost to $40,000, which applies to the current FCS indication and will be maintained for the anticipated SHTG indication across both doses. Importantly, by establishing a new price ahead of the June 30 PDUFA date, we are integrating olezarsen into 2027 payer contracting cycles, positioning us for accelerating access following approval. From a go-to-market standpoint, our full U.S. field organization is now in place, trained and deployed. Today, that team is focused on supporting Tryngolza for FCS and deepening our relationships with the key specialists who also treat SHTG.

With this expanded footprint, we are positioned to engage approximately 20,000 high-volume SHTG prescribers across the country. The DAWNZERA launch is gaining significant momentum in what is largely a switch market in the U.S. We are seeing increasing adoption across all patient segments. Patients switching from existing prophylactic therapies, patients who were previously using on-demand treatment and treatment-naive patients. Our free trial program has been very effective with high conversion to paid therapy rate to date. Just as importantly, feedback from both physicians and patients has been consistently positive, highlighting DAWNZERA’s strong efficacy, its differentiated RNA-targeted mechanism, the positive switch data, which HCPs described as “differentiating and motivating” and DAWNZERA’s patient-friendly profile that includes a self-administered auto-injector that can be stored at room temperature for up to 6 weeks.

We are also seeing a growing base of repeat prescribers, which is a key indicator that Dawnzera is providing a substantial benefit for patients. While it will take time to fully transition appropriate patients off legacy therapies, especially in a well-established market like HAE. The launch fundamentals give us confidence that DAWNZERA will contribute significantly to the increase in our commercial revenue in 2026 and beyond. Outside the U.S., DAWNZERA is now approved in the EU and our partner Otsuka has initiated launch activities. Over time, we expect ex U.S. markets to become an important contributor to the global DAWNZERA franchise. Finally, we are preparing for our first independent launch from our neurology portfolio with Zilganersen for Alexander’s disease.

On the back of the positive Phase III results, we now have FDA priority review with the PDUFA date set of September 22, and our expanded access program is underway. On the commercial side, our focus has been on continuing to strengthen current relationships and build new relationships with a highly specialized community of leukodystrophy and rare neurology HCPs, further advancing partnerships with patient advocacy groups, and ensuring the right support infrastructure is in place for diagnosis, treatment and ongoing care. Our medical affairs team has been engaging with top leukodystrophy centers, sharing data and helping to build awareness of Alexander’s disease. Our marketing and access teams are finalizing the launch strategy, and we will hire the customer-facing team closer to approval.

Zilganersen is not only an important medicine for people living with Alexander’s disease, but it’s also a template for how we will commercialize future rare first-in-class neurology therapies emerging from our pipeline. With 2 independent launches building momentum, 2 additional launches anticipated this year, and a strong pipeline behind them. We believe Ionis is well positioned to change the lives of patients around the world. With that, I’ll turn the call over to Beth. ?

Elizabeth L. Hougen: Thank you, Kyle. The strong operational execution you’ve heard about this morning translated into very strong first quarter financial results. We delivered year-over-year revenue growth and maintained disciplined expense management while continuing to invest in our current and upcoming independent launches. First quarter total revenues were $246 million, an increase of 87% compared to the first quarter of 2025. This increase was driven by year-over-year commercial revenue growth from Tryngolza and DAWNZERA and substantial R&D revenue, including approximately $95 million of milestone payments from multiple partnerships. Commercial revenue increased over 42% year-over-year in the first quarter, driven in large part from Tryngolza and DAWNZERA growth.

Tryngolza delivered over $27 million in product sales reflecting continued strong demand that was offset by an anticipated decline in net price. DAWNZERA contributed meaningfully to commercial revenue, delivering $16 million in the first quarter. an increase of 125% compared to the prior quarter. Collectively, our expanding commercial portfolio positions us for robust revenue growth. and is expected to represent an increasing share of total revenue year-over-year. Operating expenses for the quarter were in line with expectations and increased to 29% year-over-year, primarily driven by commercial investments supporting Tryngolza and DAWNZERA and launch readiness activities for olezarsen in SHTG and Zilganersen in Alexander’s disease. We ended the quarter with cash of approximately $1.9 billion.

The change in cash from year-end 2025 was primarily related to $633 million we used to repay our 0% convertible notes, which were due on April 1. The strength of our balance sheet is the result of our prudent fiscal management which enables us to make strategic investments as we advance and launch our wholly owned medicine. Our Q1 performance underscores the value of our diversified revenue model, which combines growing commercial revenue with substantial and recurring R&D revenue from partner programs. Based on our strong year-to-date financial results, accelerating launch momentum and positive outlook for the rest of the year, we are improving our 2026 financial guidance. We now expect total revenue in the range of $875 million to $900 million, an increase of $75 million versus prior guidance, with total revenue weighted slightly more towards commercial revenues.

For the first time this year, we are also providing product level guidance for Tryngolza and DAWNZERA. We expect Tryngolza product sales to be between $100 million and $110 million for the full year. and generally in line with 2025 full year Tryngolza revenue. Our guidance assumes a significant decline in second quarter Tryngolza revenue based on the updated price effective April 1 and and a steady return to growth after the June 30 approval for SHTG. We are projecting Denver product sales to be between $110 million and $120 million for the full year. Our guidance assumes DAWNZERA will continue to be a significant contributor to year-over-year growth in 2026, with revenue steadily increasing as the launch advances. We also anticipate significant R&D revenue from existing collaborations, including potential development and regulatory milestones across our partnered portfolio demonstrating that R&D revenue is indeed an important financial accelerator.

In fact, we recently learned that the first patient initiated treatment in the Phase III program for salanersen, which triggered a $45 million payment we will recognize in the second quarter. Over the balance of the year, we also are eligible to earn additional milestones tied to sapoblirson, Vibro pelacarsen and other partnered programs as they advance. We expect our 2026 operating expenses to increase in the low-teen percentage range compared to last year. This modest increase reflects our commitment to financial discipline as we bring multiple medicines directly to patients and advance our pipeline. The key drivers of expense growth will be sales and marketing investments to support Tryngolza and DAWNZERA and to ensure successful launches for olezarsen in SHTG and Zilganersen in Alexander’s disease assuming approvals.

We anticipate our R&D expenses to remain steady this year, similar to last year. As late-stage studies reach completion, we are redeploying our resources towards the drugs in our pipeline that we expect to fuel our next phase of growth. Our focus on improving operating leverage is enabling us drop the full increase in revenue guidance to the bottom line. As a result, we expect a non-GAAP operating loss between $425 million and $475 millionm a $75 million improvement over our previous guidance. This is similar to our 2025 operating loss after adjusting for the one-time sapablursen license fee we earned last year. We are projecting a 2026 year-end cash balance of greater than $1.6 billion. This reflects the repayment of the 0% convertible notes, which were due on April 1.

The strength of our balance sheet, combined with our diversified revenue streams supports our continued strategic investments in ongoing and planned launches as we advance our wholly owned pipeline. Our financial outlook reflects accelerating commercial launches, a progressing pipeline and a diversified revenue base, positioning us for continued growth and keeping us on track for cash flow breakeven in 2028. And with that, I’ll turn the call back over to Brett.

Brett Monia: Thank you, Beth. First quarter and our outlook for 2026 underscore the strength of Ionis today. With 2 successful independent launches underway, 2 more independent launches anticipated this year, a robust pipeline advancing toward multiple near- and midterm catalysts and a solid financial position that supports the continued investments we are making to maximize the value of our commercial medicines and pipeline. With all these key elements in place, we’re confident in our ability to accelerate revenue growth and deliver increasing value for patients and for all Ionis stakeholders. Now in closing, I want to highlight that this week at Ionis, we are holding our annual YWeek. It’s a time when our employees come together to hear directly from patients and caregivers about their personal stories and reinforce our purpose, which is bringing better futures to people in need.

I’ve never been prouder of the impact we are having on patient lives and clinical medicine, and I’m even more excited about the greater impact we are positioned to make in the near term and sustainably well into the future. And with that, we’ll now open the call up for questions. Sabrina?

Receive real-time insider trading and news alerts

Operator: [Operator Instructions] the first question comes from Jessica Fye of JPMorgan.

Jessica Fye: So you once again raised peak expectations for Trungolza. Can you just spend a little time elaborating on what enabled you to increase it from at least $2 billion at JPMorgan to now at least $3 billion? And can you also talk about your expectation for gross to nets on Trungolza following this price reset?

Brett Monia: Yes. Jess, thank you for the question. So our increase in peak product sales for Trungolza and SHTG and SCS combined in the U.S. to $3 billion was based on several factors. As you recall, we increased the price or the peak sales to $2 billion in January based really solely on the Phase III data and some preliminary HCP demand research that we had conducted. The demand was very high. Since then, we’ve completed our HCP demand research. But more importantly, we completed our payer research, which landed on our $40,000 annual WACC price, so price as well as priority review. Those are the biggest drivers of the increase in peak sales that we have put out today. As far as gross to net, we’re not commenting on that at this time.

Operator: The next question comes from Mike Ulz of Morgan Stanley.

Michael Ulz: Congratulations on the progress. Maybe just a question on the Tungolva trajectory for the year. You mentioned return to growth in the second half, really driven by the SHTG launch. Just curious in some of your market research, are you picking up on maybe any pent-up demand? Could we anticipate a bolus early in the launch here, just given the groundbreaking data?

Brett Monia: Kyle, would you take that, please?

Kyle Jenne: Yes, Mike, I appreciate that. And I think what’s important first is the strong performance that we saw in Q1 in terms of demand. We are — it’s the best quarter that we’ve had in terms of the FCS patient population, the number of scripts that were received and the number of patients that are starting on therapy. So that actually lends us a lot of confidence, not only in the FCS space, but also as we get closer to the June 30 PDUFA date in SHTG, I think it’s indicating that there is a lot of interest in using olezarsen very broadly in this patient population. In terms of the launch in SHTG, we do know that there are a number of patients that are waiting, right, especially the patients that have a history of acute pancreatitis, patients that are above 880, and those are really the patients that we’re going to focus on out of the gate.

The trajectory, I think, is going to be modest at the beginning here in 2026. I think the revenue guidance that Beth shared of $100 million to $110 million is consistent with that expectation, and we’ll see it steadily grow over time with that focus being on the highest risk patient population. But some of the dynamics here, as typically seen is it takes some time for the HCPs to be educated on the label. We’ve got to get those patients into those centers in order to get the prescriptions and then get the execution of the scripts to turn into patients on treatment. So it will be a build over time, and it will accumulate, and we expect modest and steady growth throughout the back half of this year.

Operator: The next question comes from Gary Nachman with Canaccord Genuity.

Gary Nachman: Congrats on the progress. So again, on SHTG, — just talk about how you expect the payer access to ramp up the timing of that, when you think it will really kick in — and you got updated guidelines for FCS. Will you be able to get that for SHTG as well? And how long before you think you could expand to a less severe patient population over time?

Brett Monia: Kyle, do you want to take — do you want to start and I can touch on the guidelines. .

Kyle Jenne: Sure. On the payer access piece, Gary, part of the price change decision that we made on April 1 to change the WACC price to 40,000 is directly with working with those payers, right? It fits into the annual review cycle as they’re getting ready for their 2027 decisions to be made. So we believe that it will help us get ahead of SHTG a little bit, not only in 2026, but also will help us in anticipation of — that being said, some payers or all payers will actually wait for the final label, right, before they make any payer coverage decisions. because they want to see what the indication statement is. They want to see what information is in the label, including acute pancreatitis and some of the other clinical study data.

that will be included in the label. So it will take a little bit of time. Some payers will say, we’re not going to review anything for 6 to 9 months, for example, that standard policy with some payers. But we hope that we’ll be able to get ahead of that with the payers that do review earlier by making that price change and also with our current interactions that we’re having leading up to the SHTG approval. So we’re going to work quickly, and I think we’re in a good spot right now in terms of the way that we’re approaching the payers. .

Brett Monia: And Gary, to your other question, we were very pleased by the fact that the cardiovascular treatment guidelines for FCS, a single do Trengolza as the treatment of choice for this disease indication. And we applaud the aggressiveness that they are taking to update their guidelines for treatments. And we believe that SHTG will be part of that in the future, which, again, we believe Tryngolza will be a treatment of choice for severe hypertriglyceridemia. They’ve been very, very supportive of the new treatments that are coming out, and we think that they will move pretty quickly. We’re also pleased by the fact that they have increased the — or updated their guidelines on Lp(a) testing, which bodes well for a potential positive Phase III readout for pelacarsen and the subsequent launch. So — it’s great news for patients, and it’s great news for our pipeline.

Unknown Executive: And in terms of the less severe patient population, we’ll start with the over 880 and over 500 with history of However, those same physicians that are treating that patient population also have patients that are 500 to 880, for example. So the education will be ongoing. We’re in the right segment HCPs in terms of our targets, right, focused on cardiology, endocrinology and lipid specialists. So they’ll see a mix of those patients. So I think some of those patients will already be picked up, especially if they have comorbidities, type 2 diabetes and/or ASC — but the broader population will take a little bit of time just for awareness and for more of the data and information to come out and more experience of using olazarsen in the SHTG population.

So there’s a lot of optimism and a lot of excitement around the category and around the use of a product like this because they’ve never seen the triglyceride-lowering effects that they’re going to see on top of standard of care and they’ve never seen the outcomes in acute pancreatitis like they’ve seen with the core and CORI data.

Operator: Next question comes from Jason Gerberry with Bank of America.

Chi Meng Fong: This is Chi on for Jason. On olezarsenSHTG, could you give us an update on the levels of liver fat you’ve observed in the core open-label extension studies — to what extent those open-label extension study data have been incorporated into the NDA as the FDA reviews the totality of the safety data — and when would you expect to present the updated OLE data later this year?

Brett Monia: Yes. Let me start, Chi. Thank you for the question, and then I’ll pass it on to Eugene. Maybe you can comment on where we are in the regulatory process for SHTG briefly. But we’re very pleased with the ongoing open-label extension data that we’re continuing to accumulate with respect to MRI assessment of hepatic fat fraction. As you recall, the increases in hepatic fat that we saw were relatively minor, interested with other modalities that have taken that silencing approach in lowering APOCIII in this patient population. And it’s completely logical, based on the mechanism of inhibition of APOCIII which leads to a rapid and substantial clearance of triglycerides in large part through the liver. . And we’ve always felt that the changes that the observations in liver fat that we’ve seen here, again, no clinical sequelae associated would be transient based on deliver just needing to have a little bit more time to clear out the delivery that’s coming — that’s been shunted through delivered.

And that’s what we’re seeing in the long-term extension data. We’re seeing a return to baseline in liver fat. Again, no clinical sequelae associated with anything in the long-term extension. And we look forward to presenting the data in the second half of this year at a major medical congress. So stay tuned for that, Eugene, you want to provide an update on regulatory?

Eugene Schneider: Yes. The applications under review. Everything is going as planned. Of course, the emerging safety data has been provided to the agency as part of routine day 90 safety update. So that’s under review now with no questions asked so far. .

Brett Monia: I’ll also add that the discontinuations in the long-term extension are extremely low. We’re seeing excellent compliance with long-term treatment in the open-label extension. So stay tuned. We’re very much looking forward to presenting the results.

Operator: The next question comes from Elly Merle of Barclays.

Unknown Analyst: This is Tejus on for Eli. — in FTE, you have a set of competitor readout coming up later this year. Curious just how you would frame those data in the context of the space and if any outcomes there would impact your peak sales view and SHTG.

Brett Monia: We’d rather not comment on competitor data that doesn’t even exist yet today. I mean, we’re looking forward to seeing any additional data that comes out this year, next year and years to come in SHTG from other programs. All I’ll say is that the Phase III data that we presented at American Heart Association and the late breaking clinical trial session last year is incredibly compelling. It’s going to be — it’s a very high bar to me with respect to efficacy, with respect to safety, with respect to tolerability, 85% reduction in acute pancreatitis which has resonated very well in the HCP community, as Kyle highlighted earlier in his prepared remarks, 72% reduction in triglycerides on top of standard of care. We’re focused on our program. We’re ready to launch in June, and we’re not — and I’ll just leave it right there.

Unknown Executive: I’ll just add, this is a large market, greater than 3 million patients that are potentially addressable here. We have a lot of confidence in the greater than $3 billion peak that we’ve put out there. That’s really based on the Phase III clinical trial outcomes that we have. It’s based on our HCP demand research. It’s based on the comprehensive payer research that we’ve done and also the final pricing decision that we made. So we stand behind the increase, and we’re excited about launching this program and getting it to as many patients as possible after the June 30 PDUFA date. .

Operator: The next question comes from Jay Olson with Oppenheimer.

Jay Olson: Congrats on the quarter, and thank you for this update. Maybe I’ll shift gears to DAWNZERA. Can you talk about how you expect the competitive landscape to evolve in HAE and any feedback that you’re getting from patients and physicians on DAWNZERA? And any color that you’re getting on what percent of patients are currently on every 8-week dosing.

Unknown Executive: Yes, happy to, Jay. Thanks for the question. The competitive landscape obviously is evolving. I mean there was some recent announcement as late as this week related to some of the dynamics in the marketplace. Keep in mind that in the United States, over 75% of the patients are currently on a prophylactic treatment. This is a switch market as we understand the dynamics to be. And we are really pleased with the momentum that we’re seeing in terms of the interest in using DAWNZERA, which is the first RNA-targeted therapy modality in order to treat these patients. The patient and HCP feedback has been extremely positive when they’ve been able to transition over to DAWNZERA or start as a naive patient. What led into this in terms of our market research is consistently being played out in the market.

Really, this is about efficacy, it’s about tolerability and convenience. And all 3 of those things are stacking up very nicely with the profile of DAWNZERA, and patients are responding very positively to the therapy. Now the majority of patients start on a 4-week dosing schedule. This is to make sure that they get transitioned over that they’re well controlled and then they have the option for the labeled indication to move over to every 8 weeks if they choose to do so. So as early in the launch as we are right now, you would anticipate that the majority of patients would be on a 4-week regimen. And we will expect over time that they’ll be able to progress on to an 8-week schedule as they’re doing well on therapy and we saw that in the clinical trial as well.

So patients are doing great. Momentum is very strong, and we’re encouraged by what we’re seeing in terms of the metrics with the launch at this point.

Operator: The next question comes from Moritz Reiterer with Guggenheim Securities.

Moritz Reiterer: This is Moritz for David. I’ll continue on, on era. Your 2026 guidance for DAWNZERA is essentially above what consensus was going into the quarter. So I was just trying to understand a little bit better what data drove this guidance number. And also if you could comment a little bit more on the current mix between new patient starts versus switches and how you expect this to evolve through the end of the year.

Unknown Executive: Yes, I’d be happy to touch on that. Thanks for the question. We had a very strong first quarter, $16 million in net product sales. This is a 128% increase over Q4 and I just spoke about the momentum that we’re seeing in this market and the dynamics and also the receptivity by both HCPs and patients as they get started and gain experience with DAWNZERA. So all of those things that I just described are really what is encouraging us, and I think where we feel very confident that $110 million to $120 million in sales this year is very achievable. In terms of the new patient starts, the majority are switches, right? This is a switch market, greater than 75% of the patients are on a prophylactic therapy in the United States.

. So it’s going to take time and time to build the revenues quarter-over-quarter. But it’s happening the way that we expected it based on what we’re seeing in the trends with Q4 as well as Q1. In addition to that, we are seeing some patients that haven’t been on a prophylactic therapy before start on DAWNZERA. So those patients, in addition to those that are being treated with an acute therapy only today that are starting on DAWNZERA. Those 3 patient segments, I think, speak to the fact that the profile is very strong in what patients and HCPs are looking for. We have a differentiated mechanism of action. And our sales execution and market access teams are doing a great job in terms of supporting these patients to get started and stay on treatment.

Operator: The next question comes from Yaron Werber of Cowen.

Unknown Analyst: This is Steven on for Yaron. Congratulations on the progress. On the collaborative revenues for the rest of the year and for maybe 2027. Can you talk about what you’re projecting because those came out a bit higher, I think, than consensus may have. Further on zilginersen, can you talk about how many patients awareness efforts have found any new updates to the size of the market. You had mentioned before that about 50% of patients have been identified. Any updates on sizing there would be helpful.

Brett Monia: Do you want to start and then Kyle, take the second part. .

Elizabeth L. Hougen: Sure. So on the collaborative revenue for this year, the way to think about is we’ve raised our revenue guidance for the total year to $875 million to $900 million. That is slightly weighted towards commercial revenue, so you can think about that split being slightly more weighted towards commercial revenue versus R&D revenues. Obviously, we’ve already realized and recognized $95 million in milestones plus our ongoing collaborative revenue, which put us well over $100 million, closer to $130 million, $140 million for the first quarter. We’ve got a host of other milestones that we could potentially earn over the remainder of this year, plus our ongoing collaborative revenue from renew a cost share and amortization.

So that is all the items that really give us confidence in the overall collaborative revenue for this year. And then for ’27, we’ve got think about it this way. There’s some very large potential milestones for approvals coming in ’27 with the Phase III data that we’re expecting to see from from pelacarsen, in particular. And those milestones are likely going to drive collaborative revenue in ’27.

Brett Monia: And our launch preparations are going really well, right?

Kyle Jenne: Yes. For Zilganersen, I just — I want to just reinforce the excitement that we’ve got around this program. This is going to be our first anticipated neurology launch program and to be able to potentially bring this therapy to patients living with Alexander’s disease, I think, is really an exciting opportunity for the community and also exciting for Ionis. In terms of the approach here, we’re really going to be focused on the patients that are currently on the clinical trial in helping get those patients moved over so that they can maintain treatment. The second area that we’ll focus on are patients that are going to be enrolled in our expanded access program, which is ongoing and going very well. . And then as you asked, what about the patients that are currently being identified and how do we help get those patients on treatment.

We believe that there are approximately 300 or so Alexander’s disease patients in the United States. About 50% of those have been identified thus far. Some of them are on therapy that I just referenced. But we are doing some expanded work through our omnichannel and through our nonpersonal promotion campaigns to help identify more and more of these patients. And really, what we want to make sure of is that they have the opportunity to experience sogonersen as the patients in the clinical trial did to potentially have the positive outcomes that we’re seeing in that trial. So patient identification will be a key area of focus. And we’re doing that while we’re really making sure that we’re going to take care of the patients that are on treatment today and those that are awaiting treatment that have already been identified.

Operator: The next question comes from Luca Issi of RBC Capital Markets.

Unknown Analyst: A quick question on why now. What happened to for the quarter. Drug is actually down 35% versus the fourth quarter what drove the weakness here? And it looks like AstraZeneca is flagging the availability of the drug now as a prefilled syringe to be administered by a healthcare provider. Did that have a negative impact on gross to net? Any color there is much appreciated.

Unknown Executive: Yes. So in Q1, we continue to see very strong demand in terms of patients on therapy as well as new patient starts. So demand is still there. Oftentimes, you see some some January, February pressure as it relates to reauthorizations and the timing of those reauthorizations, which drove some of the pressure early in the quarter. But we expect to see that pick up in subsequent quarters and return to revenue growth as we move into Q2 and beyond in the U.S. You asked about the prefilled syringe. Really that’s been put out there for optionality, right? It’s flexibility of dosing and it’s to allow HCPs to determine if they want to use the auto-injector or if they want to be able to treat these patients in some of the major centers with the prefilled syringe.

So it’s really optionality for the program. That is not impacting the gross to net at this point. It’s way too early to see any impact of that. And so I would just keep an eye towards future quarters. And again, this is the hereditary polyneuropathy space. The market is growing rapidly in the cardiomyopathy space and the eye towards cardio transform readout and getting ready for that launch is definitely where the line of sight is.

Operator: The next question is from Yanan Zhu with Wells Fargo Securities.

Yanan Zhu: Great. So wondering for the FCS, you mentioned continued growth in demand. Could you help quantify that a little bit? In terms of percent growth, given that the price change making it difficult for us to appreciate. And then can you talk about how to think about SHTG in 2027, what kind of growth could we expect from the initial launch quarters in 2026. Obviously, you guided for peak revenue, $3 billion. Any sense that how long that might take? Any color would be super helpful.

Brett Monia: Yes, and let me start and then I’ll — and Kyle already touched on what the expectations are for 2026 launch in SHTG — you can cover that again, but maybe comment on 2027. But for FCS, as Kyle mentioned earlier, our first quarter of this year is our strongest quarter to date. — on patient demand and gaining access to Tryngolza for FCS. And that’s purely a product of patient finding and the great experiences, the HCPs and patients are having with Tryngolza in managing their disease from an efficacy standpoint and from a tolerability standpoint. So demand has never been higher. We’re thrilled with what we’re seeing, and we think that, that’s going to bode quite well for the SHTG launch trajectory.

Kyle Jenne: Yes. I think what’s important, again, is to mention that in 2026, the revenue guidance is $100 million to $110 million for olazarsen this year. We expect that to grow steadily over time. As I also described, the focus initially is going to be on the high-risk SHTG patient population, over 880 or over 500 with history of — and then as we get into 2027, I would expect that more and more patients will start to come on board that are broader than that, Type 2 diabetes, ASCVD, et cetera, as I described, and the launch momentum will build. And so will the patient base as we get these patients on as HCPs get experience in seeing the triglyceride lowering levels and seeing the reduction in acute pancreatitis that were demonstrated in Core and Core 2. And I think that experience and that evidence ultimately will help us drive the trajectory into next year.

Operator: The next question comes from Salveen Richter of Goldman Sachs. .

Unknown Analyst: This is Mark on for Salveen. — are — you kind of touched on the Doner quarterly dynamics, but we were wondering what are the specific drivers for the quarter-over-quarter jump? And are there quarterly dynamics we should be aware for the rest of 2026? And how are you thinking of these dynamics going into 2017 and beyond?

Kyle Jenne: Yes. The real quarter-over-quarter growth is coming from the switch cadence that we are expecting to see, right? This being a switch market, and we expect that to continue throughout the course of this year. But that’s the big driver, right? We know that there’s a need. We know that the profile of DAWNZERA meets the need of many of those patients being efficacy, tolerability and convenience. And we’ve got the data with the Switch data to help support how to move those patients over from existing prophylactic treatments over to DAWNZERA. And as HCPs are gaining experience, we’re seeing more and more HCPs not only prescribed for the first time, but we’re also seeing those that have used the treatment before, use it again and again. . So I think that plus payer coverage tells us that we’ve got an optimistic outlook in terms of what 2026 looks like. And I think the $110 million to $120 million guidance is in line with that expectation.

Eugene Schneider: And we have time for 1 more question, please. .

Operator: The last question comes from Myles Minter with William Blair.

Myles Minter: Congrats on the car. Just on the TTR cardiomyopathy market, if I did settle for a potential generic entry from Vindemax in mid-2031 versus something like in 2035. Does that change the way you’re AstraZeneca are thinking about the cardiomyopathy moving market moving forward? And how much emphasis you’re going to place on that are stabilized of background therapy subgroup in cardio TTR transform.

Brett Monia: The news that has been emerging this past week or so on genericizing tafamidis versus brand pricing is not come terribly surprising to us. is consistent with our product sales guidance that we’ve put out there with AstraZeneca previously. We believe we remain completely and believe that the filing or class will end up being the mechanism of choice for TTR amyloidosis. We believe that the silencer class will be utilized as first-line treatment. — as well as in those patients that inevitably progress on stabilizers and combination usage to your question. We’ll also be will be utilized very, very robustly, especially if there’s data supporting that combination usage will add further benefit to these patients that inevitably are progressing on current treatments.

. And our study is designed to actually generate the data that we believe could be convincing to HCPs who are asking the question whether or not a combination of a stabilizer with a silencer will add further benefit to these patients. So — it’s the largest study ever conducted in ATTR cardiomyopathy and the combination subgroup is quite sizable. So we’re looking forward to the data in the second half of this year. and we’re prepared to submit the NDA by the end of this year and to launch next year. So thank you, Myles, for that — thank you for the question, Myles. Thank you, everybody, who joined us today and participated on our call. We’re looking forward to an outstanding year and sharing our progress along the way. So until then, thank you, and have a great day, everybody.

Elizabeth L. Hougen: Goodbye.

Operator: Thank you for attending today’s presentation. You may now disconnect.

Receive real-time insider trading and news alerts